IgG-related disease (IgG-RD) is a rare form of autoimmune sclerosing disease, characterised by elevated serum IgG and tissue IgG levels, specific histopathological findings, multiorgan involvement and adequate response to glucocorticoid treatment. The low incidence and the heterogeneous nature of the disease has made consensus on diagnostic criteria for IgG-RD difficult. Whether sclerosing mesenteritis (SM) is considered a manifestation of IgG-RD is strongly debated. We present the case of a patient with a history of rheumatoid arthritis who presented with a calcified abdominal mass. She was found to have an isolated, pedunculated mesenteric mass positive for IgG and concurrently elevated serum IgG levels. Clinical features did not classify her disease as either SM or IgG-RD as currently described in consensus statements. Concurrent diagnoses of IgG-RD, SM and other autoimmune disorders, as well as postoperative recommendations for resected isolated IgG-positive masses, are discussed.
In this paper, a novel LPWAN technology, ZCNET, is proposed, which achieves significantly higher network capacity than existing solutions, such as LoRa, Sigfox, and RPMA. The capacity boost of ZCNET is mainly due to two reasons. First, a ZCNET node transmits signals that occupy a small fraction of the signal space, resulting in a low collision probability. Second, ZCNET supports 8 parallel root channels within a single frequency channel by using 8 Zadoff-Chu (ZC) root sequences. The root channels do not severely interfere with each other, mainly because the interference power is spread evenly over the entire signal space. A simple ALOHA-style protocol is used for medium access, with which a node randomly chooses the root channel and the range it occupies within the root channel. ZCNET has been extensively tested with both real-world experiments on the USRP and simulations, and the results confirm that ZCNET achieves significant gains over LoRa, Sigfox, and RPMA. ZCNET will likely better accommodate the explosive growth of IoT network sizes and meet the demand of IoT applications.
Introduction: Medication-related osteonecrosis of a jaw can occur in patient taking antiresorptive medication mainly as Nitrogen-containing Bisphosphonates, longer and intravenous treatment by bisphosphonates and patient who received tyrosine kinase inhibitor. We report an evaluation of the association of Pentoxifylline-Tocopherol to reduce or to treat the side effects on jawbone of the antiresorptive medications. Patients and methods: Six patients were selected two of them with intractable cases of MRONJ due to antiresorptive medication (Nitrogen-containing bisphosphonates and tyrosine kinase inhibitor) and four of them regarded as risky patients because taking Nitrogen-containing Bisphosphonates for at least two years and having to undergo jawbone surgery. Results: following the prescription of pentoxifylline -tocopherol, to prevent the occurrence of an MRONJ or to protect the surgical procedure for surgical removal of necrotic exposed bone, at the last follow up no adverse effects were identified and clinical appreciation was confirmed by radiological examinations. Conclusion: the association Pentoxifylline -Tocopherol has proven its efficacy in preventing or treating MRONJ bu. It was also critical to highlight the MRONJ risk in patients under monoclonal antibodies at the time of these molecules are rising, and to emphasize on the action of pentoxifylline-tocopherol in the management of the side effects of various monoclonal antibodies on the jaw bone
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.